Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 16 peer-reviewed journal articles Updated
Pathology

Diagnosing PCT: Understanding Your Lab Tests

At a Glance

Diagnosing Porphyria Cutanea Tarda (PCT) involves two main steps: confirming a massive elevation of porphyrins (like uroporphyrin) in your urine or blood, and screening for underlying triggers that unmask the disease, such as Hepatitis C, HIV, or iron overload.

Diagnosing Porphyria Cutanea Tarda (PCT) is a two-step process. First, your doctor must confirm that you have the condition by identifying a specific “porphyrin fingerprint.” Second, they must search for the “trigger” that caused the disease to surface. Understanding your lab reports can help you feel more in control of this process.

Step 1: Confirming the “Porphyrin Fingerprint”

The gold standard for diagnosing PCT is measuring the levels of porphyrins in your urine, plasma (blood), or stool [1][2]. Many patients initially notice their urine is dark or tea-colored; this lab test is simply quantifying what causes that color change [3].

  • Urine Porphyrin Profile: In a person with PCT, the urine will show a massive elevation of porphyrins. Specifically, uroporphyrin and heptacarboxylporphyrin will be significantly higher than other types [4][1].
  • Plasma Porphyrin Profile: Your blood will also show high levels of porphyrins. Labs often look for a specific “fluorescence peak” around 620 nm, which is characteristic of PCT [1].
  • The Wood’s Lamp Test: This is a simple, quick test where a doctor shines a special ultraviolet light (Wood’s lamp) on a urine sample. If porphyrin levels are high, the urine will often glow a bright coral-red [5][6]. Note: While this is a fascinating historical test that can offer immediate clues, modern clinics often bypass it in favor of direct, precise biochemical blood and urine testing.

Auditing Your Labs: PCT vs. Pseudoporphyria

A critical part of your diagnosis is making sure you don’t have pseudoporphyria. This condition looks exactly like PCT on the skin but is caused by medications (like naproxen) or kidney issues rather than an enzyme deficiency [7][8].

  • In PCT: Porphyrins in your blood and urine are very high [9].
  • In Pseudoporphyria: Porphyrins in your blood and urine are normal or only slightly elevated [8].

Step 2: Finding the Trigger

Because PCT is almost always “unmasked” by another health factor, a diagnosis is not complete until your doctor screens you for three specific conditions:

  1. Hepatitis C (HCV): This virus is one of the most common triggers for PCT because it directly interferes with the liver’s ability to process porphyrins [9][4]. Screening for HCV is standard because treating the virus can often put the PCT into remission [10][11].
  2. Iron Overload and HFE Mutations: Excessive iron in the liver is a primary driver of PCT [12]. Your doctor should test your ferritin levels and may test for HFE gene mutations, which cause a condition called hemochromatosis (hereditary iron overload) [13][3].
  3. HIV: HIV is a known risk factor for developing PCT [14]. Like Hepatitis C, treating HIV with antiretroviral therapy can often lead to a significant improvement in PCT symptoms [15].

Why “HPLC” Matters

You may see the term HPLC (High-Performance Liquid Chromatography) on your lab report. This is the advanced technology labs use to “fractionate” or separate the different porphyrins [9]. This precise separation is what allows your care team to be 100% sure that your profile matches PCT and not another, rarer form of porphyria [16].

Common questions in this guide

What is the main lab test to diagnose Porphyria Cutanea Tarda (PCT)?
The gold standard for diagnosing PCT is measuring the levels of porphyrins in your urine, blood, or stool. A massive elevation of specific porphyrins, particularly uroporphyrin and heptacarboxylporphyrin, confirms the disease.
Why does my doctor test me for Hepatitis C or HIV if I have PCT?
PCT is almost always unmasked by another health factor that affects the liver. Conditions like Hepatitis C, HIV, and iron overload are common triggers, so screening for them is a standard and necessary part of a complete PCT diagnosis.
What is the difference between PCT and pseudoporphyria?
Both conditions cause similar skin symptoms, but pseudoporphyria is triggered by medications (like naproxen) or kidney issues rather than an enzyme deficiency. In PCT, porphyrin levels are extremely high, whereas they remain normal or only slightly elevated in pseudoporphyria.
What does HPLC mean on my porphyria lab report?
HPLC stands for High-Performance Liquid Chromatography. It is the advanced laboratory technology used to separate different porphyrins so your care team can confirm you specifically have PCT and not another type of porphyria.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Did my urine test show a specific increase in 'uroporphyrin' and 'heptacarboxylporphyrin'?
  2. 2.Since I have PCT, have we already screened me for Hepatitis C, HIV, and the HFE (hemochromatosis) gene?
  3. 3.If my porphyrin levels are normal but I have the symptoms, could this be pseudoporphyria caused by my current medications?
  4. 4.Should we check my iron and ferritin levels to see if iron overload is a factor in my case?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (16)
  1. 1

    Practical recommendations for biochemical and genetic diagnosis of the porphyrias.

    Aarsand AK, To-Figueras J, Whatley S, et al.

    Liver international : official journal of the International Association for the Study of the Liver 2025; (45(3)):e16012 doi:10.1111/liv.16012.

    PMID: 38940544
  2. 2

    Stability of plasma and erythrocyte porphyrins: implications for diagnosis and monitoring of erythropoietic protoporphyria.

    Schulenburg-Brand D, Maw K, Bentley LA, et al.

    Journal of clinical pathology 2026; (79(3)):206-211 doi:10.1136/jcp-2025-210393.

    PMID: 41162157
  3. 3

    [Porphyria cutanea tarda].

    Mistegård J, Christiansen AL, Vestergaard C, et al.

    Ugeskrift for laeger 2025; (187(38)) doi:10.61409/V11240832.

    PMID: 41025764
  4. 4

    Blistering Disease During the Treatment of Chronic Hepatitis C With Ledipasvir/Sofosbuvir.

    Cash J, Skinner A, Cash S, et al.

    Federal practitioner : for the health care professionals of the VA, DoD, and PHS 2019; (36(Suppl 2)):S11-S13.

    PMID: 30983856
  5. 5

    Bullous lesions following phototherapy in a newborn.

    Toscano MM, Cintra FF, Resende LO, et al.

    Einstein (Sao Paulo, Brazil) 2023; (21()):eRC0256 doi:10.31744/einstein_journal/2023RC0256.

    PMID: 37255061
  6. 6

    Drug-Induced Pseudoporphyria: A Case Report.

    Jangid SD, Saoji V, Madke B, Bhatt DM

    Cureus 2024; (16(4)):e57574 doi:10.7759/cureus.57574.

    PMID: 38707054
  7. 7

    Porphyria cutanea tarda: an intriguing genetic disease and marker.

    Handler NS, Handler MZ, Stephany MP, et al.

    International journal of dermatology 2017; (56(6)):e106-e117 doi:10.1111/ijd.13580.

    PMID: 28321838
  8. 8

    Clinical Characteristics and Inciting Agents for Pseudoporphyria: The Mayo Clinic Experience, 1996-2020.

    Kumar AB, Asamoah EM, Wetter DA, et al.

    Advances in skin & wound care 2024; (37(8)):406-411 doi:10.1097/ASW.0000000000000176.

    PMID: 39037094
  9. 9

    Resolution of subclinical porphyria cutanea tarda after hepatitis C eradication with direct-acting anti-virals.

    Sastre L, To-Figueras J, Lens S, et al.

    Alimentary pharmacology & therapeutics 2020; (51(10)):968-973 doi:10.1111/apt.15703.

    PMID: 32294804
  10. 10

    Ledipasvir/Sofosbuvir Is Effective as Sole Treatment of Porphyria Cutanea Tarda with Chronic Hepatitis C.

    Bonkovsky HL, Rudnick SP, Ma CD, et al.

    Digestive diseases and sciences 2023; (68(6)):2738-2746 doi:10.1007/s10620-023-07859-8.

    PMID: 36811718
  11. 11

    Evolution of HCV associated porphyria cutanea tarda after HCV sustained virologic response by direct acting antivirals.

    García-Fraile LJ, García-Buey L, Alonso Cerezo C, et al.

    Gastroenterologia y hepatologia 2022; (45(4)):249-255 doi:10.1016/j.gastrohep.2021.09.001.

    PMID: 34562521
  12. 12

    Porphyria cutanea tarda: a unique iron-related disorder.

    Leaf RK, Dickey AK

    Hematology. American Society of Hematology. Education Program 2024; (2024(1)):450-456 doi:10.1182/hematology.2024000664.

    PMID: 39644053
  13. 13

    Hepatic porphyria: A narrative review.

    Arora S, Young S, Kodali S, Singal AK

    Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology 2016; (35(6)):405-418 doi:10.1007/s12664-016-0698-0.

    PMID: 27796941
  14. 14

    Human immunodeficiency virus and risk of porphyria cutanea tarda: a possible association examined in a large hospital.

    Aguilera P, Laguno M, To-Figueras J

    Photodermatology, photoimmunology & photomedicine 2016; (32(2)):93-7 doi:10.1111/phpp.12222.

    PMID: 26576928
  15. 15

    Porphyria cutanea tarda in a HIV- positive patient.

    Franzon VA, Mikilita ES, Camelo FH, Camargo R

    Anais brasileiros de dermatologia 2016; (91(4)):520-3.

    PMID: 27579753
  16. 16

    Porphyria Cutanea Tarda in a Patient With Hereditary Hemochromatosis: A Complex Overlap Disorder.

    DeMaria BL, Franke AJ

    Cureus 2024; (16(11)):e74091 doi:10.7759/cureus.74091.

    PMID: 39568488

This page explains PCT diagnostic tests for educational purposes only. Always discuss your specific lab results and diagnostic screening with your physician or hematologist.

Get notified when new evidence is published on Porphyria cutanea tarda.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.